



## PRESS RELEASE

March 17, 2021

# ZICCUM AB accepted as member of NIIMBL - prestigious US biopharma innovation group

**Swedish vaccine innovation company ZICCUM AB has been accepted as a member of NIIMBL, the US National Institute for Innovation in Manufacturing Biopharmaceuticals. NIIMBL drives innovation and uptake of new technologies within biopharmaceutical manufacturing in the US. Ziccum's LaminarPace technology air-dries vaccines and biologics at ambient temperatures, producing stable, dry-powder vaccines requiring no Cold Chain for storage or transportation.**

NIIMBL is a public-private partnership spanning government, the biopharma industry, academia, trade organisations and more. It is co-funded by the the US National Institute of Standards and Technology (NIST), the U.S. Department of Commerce and members. NIIMBL's mission is accelerating the development and uptake of next-generation biopharmaceutical manufacturing technologies within the US.

Ziccum CEO Göran Conradson: "It is an honour to be accepted as a member of NIIMBL, especially as a foreign bio-research company. Right now, innovation in biopharmaceutical manufacturing has never been more urgent. It is a global priority for all of us. We look forward to being active, collaborative and responsible members."

### READ MORE

- Read more about NIIMBL [here](#).
- Read more about LaminarPace [here](#).
- Ziccum's plans for regional Fill and Finish plants [here](#).
- Ziccum technology preparing for pandemics and reducing vaccine waste [here](#).

For more information about Ziccum, please contact:

---

Göran Conradson: CEO Ziccum AB

Mail: [conradson@ziccum.com](mailto:conradson@ziccum.com)

Mobile: +46 709 61 55 99

### Certified Adviser

Erik Penser Bank AB

Mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

Phone: +46 8 463 83 00

## About Ziccum

---

Ziccum develops new thermostable versions of the world's most urgently needed, life-saving vaccines. The Company's patented technology, LaminarPace, enables the production of new, gently air-dried formulations that can be transported easily and cost-effectively, with no need for a costly and complicated cold chain, all the way from the factory to the last child in the last mile of the supply chain.

## Attachments

---

[ZICCUM AB accepted as member of NIIMBL - prestigious US biopharma innovation group](#)